We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.
Molecular definition of 17P11-P12 amplification in multiple myeloma / S. Fabris, L. Agnelli, K. Todoerti, L. Mosca, I. Kwee, D. Ronchetti, D. Intini, G. Ciceri, F. Berton, G. Lambertenghi Deliliers, A. Neri. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:Suppl. 3(2007), pp. 139-139. ((Intervento presentato al 41. convegno Congress of the Italian Society of Hematology tenutosi a Bologna nel 2007 [10.3324/haematol.10564].
Molecular definition of 17P11-P12 amplification in multiple myeloma
S. Fabris;L. Agnelli;K. Todoerti;D. Ronchetti;D. Intini;G. Ciceri;G. Lambertenghi Deliliers;A. Neri
2007
Abstract
We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
